Skye Bioscience Inc expected to post a loss of 31 cents a share - Earnings Preview
Skye Bioscience Inc
SKYE is expected to show no change in quarterly revenue when it reports results on November 5 (estimated) for the period ending September 30 2025LSEG's mean analyst estimate for Skye Bioscience Inc is for a loss of 31 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Skye Bioscience Inc is $10.00, about 84.5% above its last closing price of $1.55
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.32 | -0.31 | -2.69 | Missed | -763.8 |
Mar. 31 2025 | -0.29 | -0.29 | -0.28 | Beat | 2.4 |
Dec. 31 2024 | -0.27 | -0.28 | -0.24 | Beat | 15.5 |
Sep. 30 2024 | -0.25 | -0.25 | -0.10 | Beat | 60.1 |
Jun. 30 2024 | -0.21 | -0.19 | -0.20 | Missed | -2.6 |
Mar. 31 2024 | -0.16 | -0.16 | -0.18 | Missed | -12.5 |
Dec. 31 2023 | -0.38 | -0.38 | -0.63 | Missed | -65.8 |
This summary was machine generated November 3 at 11:34 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
